Investigators characterized cardiac inflammation in Kawasaki disease using 64-plex immunofluorescence on autopsy coronary artery specimens. The study team reported spatially organized immune cell clusters—neutrophils, macrophages, and T cells—aligned with areas of arterial wall destruction and remodeling. Short, focal immune aggregates sat adjacent to broad zones of structural disturbance. The authors noted that these organized infiltrates appeared to directly associate with local tissue injury rather than forming as a uniform diffuse process across the vessel wall.
Cellular mapping also identified disrupted relationships between stromal and muscle cells within affected arterial segments. In some regions, stromal elements were dissociated from smooth muscle architecture; in others, muscle cells appeared replaced or obscured by dense immune infiltrates. The investigators did not report single-cell transcriptional profiles in this preprint; spatial protein localization was the primary modality described.
Spatial analysis revealed expression of the innate immune sensor STING in myeloid cells within Kawasaki disease coronary artery tissues. The cohort showed colocalization of STING signal with macrophage markers in situ. Authors reported that STING staining was concentrated in these myeloid-rich areas rather than being widespread across all cellular compartments. The data indicated a focal upregulation of this pathway within innate immune cells that occupy sites of vascular injury.
Investigators framed this observation as mechanistically relevant, given the known role of STING in innate immune signaling. The preprint did not provide clinical human biomarker thresholds or quantitative clinical correlations such as serum STING levels or patient outcome associations. The study team limited claims to tissue-level spatial expression and did not extrapolate to circulating biomarkers or therapeutic windows in patients.
The study tested functional relevance using a mouse model of Kawasaki disease. Pharmacological and genetic inhibition of STING reduced the development of vasculitis in that model, the authors reported. Experimental blockade produced an observable decrease in vasculitic pathology compared with controls. Short experimental summaries described both genetic loss-of-function approaches and drug-mediated inhibition; detailed dosing regimens, timing, or safety readouts were not reported in the preprint.
These murine results supported a causal role for STING in driving vascular inflammation within the experimental system. The study team observed phenotype modification after STING inhibition, which the authors used to justify further consideration of STING as a therapeutic target. The authors did not claim that the mouse interventions predictably map to effective or safe human therapies without additional preclinical and clinical work.
Tissue-level profiling revealed inflammatory injury extending beyond the coronaries. The cohort showed diffuse myocardial inflammation in addition to the focal coronary arteritis. Authors described disrupted stromal–muscle cell relationships and immune cell colocalization patterns not limited to the arterial wall. This suggests cardiac involvement in KD that includes parenchymal myocardial regions, not solely the epicardial coronary vasculature.
The investigators emphasized that spatially resolved profiling exposed heterogeneity in tissue compartments—vascular wall destruction in some areas, more diffuse interstitial inflammation in others—indicating a complex anatomic distribution of injury. The preprint did not include longitudinal sampling or clinical imaging correlates to define the temporal evolution of these patterns during acute versus convalescent phases.
The authors derived conclusions from autopsy tissues and an experimental mouse model; human interventional evidence is not included in this preprint. The report did not present dosing, safety, or pharmacokinetic data for the pharmacological inhibitors used in mice, and it did not include human clinical trial data. Investigators did not provide details about patient selection criteria for the autopsy specimens in the abstracted material available here.
Key questions remain. Will STING inhibition translate into clinical benefit for children with treatment-resistant or severe Kawasaki disease? What are the safety parameters and therapeutic window in humans? Which patient subgroups, if any, are most likely to benefit? The authors noted that identifying STING in KD tissue and showing efficacy in a murine model make the pathway a candidate for further preclinical safety testing and carefully designed clinical trials, but those next steps were not part of this report.
Limitations documented in the preprint include the observational nature of spatial profiling in human autopsy tissue and reliance on a mouse model for functional testing; the authors did not present human interventional data. The study ends on these concrete gaps and on the need for targeted preclinical safety work and translational studies to determine whether STING-directed therapies could be viable in pediatric KD.